Xiangya Hospital of Central South University

CRISPR Clinical Trial Update – Beta Thalassemia
Mar. 10, 2021

This week’s clinical update looks at two clinical trials for beta thalassemia using CRISPR-Cas9-edited donor-derived haematopoeitic stem cells (HSCs).

Xiangya Hospital of Central South University

Transfusion-dependent Beta-thalassemia, TDT, (NCT06314529)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Multiple Myeloma, MM, (NCT03492268)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IND Enabling
Phase I
Phase II
Phase III
B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT03232619)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Malignancies, (NCT03229876)
Sponsors:
Bioray Laboratories - Shanghai Bangyao Biotechnology Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, BT, (NCT04211480)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine